

Adaptimmune Therapeutics PLC
Form 6-K
September 15, 2015

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934

For the Month of September, 2015

Commission File Number: 001-37368

ADAPTIMMUNE THERAPEUTICS PLC

(Translation of registrant's name into English)

101 Park Drive, Milton Park
Abingdon, Oxfordshire OX14 4RY
United Kingdom

Edgar Filing: Adaptimmune Therapeutics PLC - Form 6-K

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes ☐ No ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes ☐ No ☐

Other Events

On September 14, 2015, Adaptimmune Therapeutics plc (the Company) issued a press release announcing that on September 17, 2015, James Noble, the Company's Chief Executive Officer, will be presenting at the 2015 Morgan Stanley Global Healthcare Conference and Dr. Helen Tayton-Martin, the Company's Chief Operating Officer, will be presenting at the 2015 Bank of America Merrill Lynch Global Healthcare Conference. The press release is attached as Exhibit 99.1 and the presentation to be given at the 2015 Morgan Stanley Global Healthcare Conference is attached as Exhibit 99.2 and both exhibits are incorporated by reference herein. A shortened version of Exhibit 99.2 will be presented at the 2015 Bank of America Merrill Lynch Global Healthcare Conference.

Exhibits

99.1 Press release dated September 14, 2015

99.2 Presentation materials dated September 2015

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Adaptimmune Therapeutics plc

By:	/s/ Margaret Henry
Name:	Margaret Henry
Title:	Corporate Secretary

Date: September 15, 2015